Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Retatrutide: A Triple Agonist with Unprecedented Efficacy Retatrutide (LY3437943) is a novel triple incretin agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog
Ozempic is a once-a-week injection with multiple dosing strengths (0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg, and 2.4 mg)
Some patients may experience mild redness or soreness at the infusion site, which usually resolves quickly
The ideal injection site depends on your age and the comfort level of the person administering the injection
Your GP can assess metabolic health through tests such as HbA1c, fasting glucose, and lipid profiles if you have symptoms suggesting metabolic dysfunction
